Soluble TWEAK level: is it a marker for cardiovascular disease in long-term hemodialysis patients?

GUNGOR O., KIRCELLI F., AŞCI G. , Carrero J. J. , TATAR E., DEMIRCI M. S. , ...Daha Fazla

JOURNAL OF NEPHROLOGY, cilt.26, ss.136-143, 2013 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 26 Konu: 1
  • Basım Tarihi: 2013
  • Doi Numarası: 10.5301/jn.5000121
  • Sayfa Sayıları: ss.136-143


Background: Reduced soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) levels follow declining renal function, are strongly associated with endothelial dysfunction and predict cardiovascular events in nondialyzed chronic kidney disease patients. In contrast, elevated levels of sTWEAK predict poor survival in hemodialysis (HD) patients. Recent evidence suggests a role for sTWEAK in the pathophysiology of vascular calcification. The aim of the study was to investigate plausible links between sTWEAK, atherosclerosis, arterial stiffness and vascular calcification in HD patients.